# A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole

> **NCT01786382** · PHASE1 · COMPLETED · sponsor: **Presidio Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Pharmacokinetic Assessments in Healthy Volunteers

## Interventions

- **DRUG:** PPI-668
- **DRUG:** Midazolam
- **DRUG:** Omeprazole
- **DRUG:** Telaprevir

## Key facts

- **NCT ID:** NCT01786382
- **Lead sponsor:** Presidio Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01786382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01786382, "A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01786382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*